The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study

✍ Scribed by Yavuz Selvi; Abdullah Atli; Adem Aydin; Lutfullah Besiroglu; Pinar Ozdemir; Osman Ozdemir

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 339 KB
• Volume: 26
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.1169

✦ Synopsis

Abstract

Objective

To investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive‐compulsive disorder (OCD) patients who did not show a ≥35% decrease in the Yale‐Brown Obsessive‐Compulsive Scale (Y‐BOCS) after 12‐week monotherapy with selective serotonin reuptake inhibitors (SSRIs).

Methods

The study consists of two different periods of treatment: a 12‐week prospective period to determine resistance to SSRI treatment and an 8‐week single‐blind addition period for refractory patients only. Ninety patients were randomly assigned to receive one of the SSRI treatments. Sixty‐nine patients (76.6%) completed the 12‐week SSRI monotherapy period. Forty‐one patients (59.4%) were considered refractory and were randomised to receive either risperidone (20 patients, 3 mgr daily) or aripiprazole (21 patients, 15 mgr daily) as augmentation to SSRI treatment. Sixteen patients (76.2%) in the aripiprazole group and 18 patients (84%) in the risperidone group completed the 8‐week treatment period.

Results

Eight patients (50%) in aripiprazole and 13 patients (72.2%) in risperidone group met response criteria of Y‐BOCS decrease ≥35% at the end of the study. The risperidone group showed a significant improvement in Y‐BOCS obsession scores compared with aripiprazole.

Conclusions

The present findings suggest that risperidone may be more effective than aripiprazole. Copyright © 2011 John Wiley & Sons, Ltd.